These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38870368)

  • 1. Onabotulinumtoxina (craniotomy scar combined with cranial suture line injections) for persistent post craniotomy headache: Case series with long-term follow-up.
    Leon J; Rozen TD; Bhatt AA
    Cephalalgia; 2024 Jun; 44(6):3331024241259452. PubMed ID: 38870368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache.
    Navratilova E; Oyarzo J; Anderson T; Broide RS; Subramaniam SR; Vazquez-Cintron EJ; Brin MF; Schwedt TJ; Dodick DW; Porreca F
    Cephalalgia; 2022 Oct; 42(11-12):1194-1206. PubMed ID: 35546268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed-onset post-craniotomy headache responsive to botulinum toxin A: a case series.
    Ranoux D; Martiné G; Espagne G; Salle H; Caire F
    Acta Neurochir (Wien); 2017 Aug; 159(8):1375-1378. PubMed ID: 28555271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
    J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Jan; 20(1):10. PubMed ID: 30669961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological, functional and neurological outcomes of craniectomy versus cranial vault remodeling for isolated nonsyndromic synostosis of the sagittal suture: a systematic review.
    Thwin M; Schultz TJ; Anderson PJ
    JBI Database System Rev Implement Rep; 2015 Sep; 13(9):309-68. PubMed ID: 26470674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
    Silberstein SD; Diener HC; Dodick DW; Sommer K; Lipton RB
    Headache; 2024; 64(7):838-848. PubMed ID: 38982666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment.
    Guerzoni S; Pellesi L; Baraldi C; Pini LA
    J Headache Pain; 2015; 17():48. PubMed ID: 27146068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
    J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Makris N; Kararizou E
    J Headache Pain; 2018 Sep; 19(1):87. PubMed ID: 30225735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
    J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
    Dodick DW; Silberstein SD; Lipton RB; DeGryse RE; Adams AM; Diener HC
    Cephalalgia; 2019 Jul; 39(8):945-956. PubMed ID: 31112399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational, open-label, non-randomized study on the efficacy of onabotulinumtoxinA in the treatment of nummular headache: The pre-numabot study.
    García-Azorín D; Trigo-López J; Sierra Á; Blanco-García L; Martínez-Pías E; Martínez B; Talavera B; Guerrero ÁL
    Cephalalgia; 2019 Dec; 39(14):1818-1826. PubMed ID: 31272194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peri-Incisional Botulinum Toxin for Chronic Postcraniotomy Headache After Traumatic Brain Injury: A Case Series.
    MacKenzie HM; Teasell R; Miller TA; Sequeira K
    PM R; 2015 Jul; 7(7):785-788. PubMed ID: 25731891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
    Negro A; Curto M; Lionetto L; Martelletti P
    J Headache Pain; 2015; 17():1. PubMed ID: 26792662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R
    J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.